A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Overview of attention for article published in BMC Cancer, January 2022

Altmetric Badge

Mentioned by

twitter: 1 tweeter

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 1 tweet from an account with 226 followers.

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer https://t.co/BUaL9YI6AT

04 Jan 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.